What do systematic reviews say?

Antiplatelet drug vs placebo

• Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 280 participants
  Very low

Dual antiplatelet therapy vs one antiplatelet agent

• Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 3020 participants
  Low

Antiplatelet therapy vs placebo

• Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 50 participants
  Very low

Orexin antagonists vs placebo

• Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 274 participants
  Moderate

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 344 participants
  Low
• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 108 participants
  Moderate

Donepezil 10 mg/day vs placebo

• Donepezil for dementia due to Alzheimer's disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1102 participants
  Moderate
• Donepezil for dementia due to Alzheimer's disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1348 participants
  Moderate

Donepezil 23 mg/day vs donepezil 10 mg/day

• Donepezil for dementia due to Alzheimer's disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1704 participants
  Moderate

Donepezil 10 mg/day vs placebo

• Donepezil for dementia due to Alzheimer's disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1130 participants
  Moderate
• Donepezil for dementia due to Alzheimer's disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 1757 participants
  Moderate

Donepezil 23 mg/day vs donepezil 10 mg/day

• Donepezil for dementia due to Alzheimer's disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1370 participants
  Moderate

Donepezil 10 mg/day vs donepezil 5 mg/day

• Donepezil for dementia due to Alzheimer's disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 303 participants
  Moderate

Rivastigmine vs placebo

• Rivastigmine for Alzheimer's disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 3232 participants
  Moderate
• Rivastigmine for Alzheimer's disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 3205 participants
  Moderate

Donepezil 10 mg/day vs donepezil 5 mg/day

• Donepezil for dementia due to Alzheimer's disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 818 participants
  Moderate

Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo

The review found no eligible studies for this question.

• Vitamin E for Alzheimer's dementia and mild cognitive impairment 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo

• Vitamin E for Alzheimer's dementia and mild cognitive impairment 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 272 participants
  Moderate

B vitamins vs placebo

• Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 317 participants
  Low
• Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 241 participants
  Low

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 411 participants
  Very low